Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 4 study of Keytruda (pembrolizumab) in glioblastoma multiforme
2020-006143-26Phase 4Active
- Sponsor
- Medical University of Silesia
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pembrolizumab in glioblastoma (GBM), sponsored by Medical University of Silesia. Primary endpoint: Safety and tolerability. Started Feb 2021; status: active.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2020-006143-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006143-26.